Celldex Therapeutics (NASDAQ:CLDX) has climbed 3.64% in the past week and advanced 5.96% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 4.88% and the outperformance has advanced to 4.99% for the last 4 weeks period.
Celldex Therapeutics (NASDAQ:CLDX): The stock opened at $4.42 on Friday but the bulls could not build on the opening and the stock topped out at $4.45 for the day. The stock traded down to $4.25 during the day, due to lack of any buying support eventually closed down at $4.27 with a loss of -3.17% for the day. The stock had closed at $4.41 on the previous day. The total traded volume was 7,266,403 shares.
The company shares have dropped -83.29% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $28.08 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $4.14 and the 200 Day Moving Average price is recorded at $7.58.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Catlin Avery W, officer (Sr. VP & CFO) of Celldex Therapeutics, Inc., had unloaded 25,000 shares at an average price of $18 in a transaction dated on November 23, 2015. The total value of the transaction was worth $450,000.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Jefferies downgrades the rating on Celldex Therapeutics (NASDAQ:CLDX). The brokerage firm has issued a Hold rating on the shares. The shares were previously rated Buy. The Analysts at the ratings agency lowers the price target from $31 per share to $4 per share. The rating by the firm was issued on March 8, 2016. Currently the company Insiders own 4.2% of Celldex Therapeutics shares according to the proxy statements. Institutional Investors own 85.68% of Celldex Therapeutics shares.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.